{"entity":{"id":"nct05585320","kind":"trial","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Dabrafenib, Pembrolizumab in melanoma and non-small-cell lung cancer, run by Immuneering Corporation, active and no longer recruiting.","summary":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05585320 by Immuneering Corporation, with 209 participants enrolled, started 2022-10-31 and due to reach its primary completion in 2026-06. Interventions recorded: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E). Conditions listed: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05585320","url":"https://clinicaltrials.gov/study/NCT05585320"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel","dabrafenib","pembrolizumab"],"companies":["immuneering"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05585320","phase":"1/2","setting":"A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors","sponsor":"Immuneering Corporation","enrolled":209,"outcomes":[]},"route":"/trials/nct05585320/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/"}]}}